Madrigal Pharmaceuticals Stock More Than Doubles on ‘NASH’ Breakthrough

After years of failed efforts to find a treatment for the liver condition known as NASH, biotechnology firm

Madrigal Pharmaceuticals

delivered an unexpected success on Monday.

In a Phase 3 trial of its drug resmetirom, Madrigal (ticker: MDGL) said that 30% of patients who received a higher dose of the treatment showed resolution of NASH, and 26% of patients who received a lower dose showed resolution. The company also said that 26% of patients at the higher dose level, and 24% at the lower dose level, saw improvement in liver fibrosis.


Leave a Comment

Your email address will not be published. Required fields are marked *